Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 16, 2017 JNK, AGZ, AMJ, PSDV, DLR, DGX Are Seasonally Ripe To Go Up In the Next Five Weeks
March 16, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of SPDR Barclays Capital High Yield Bond ETF (NYSE:JNK), iShares Barclays Agency Bond Fund (NYSE:AGZ), JPMorgan Alerian MLP Index ETN (NYSE:AMJ), pSivida Corp. (NASDAQ:PSDV), Digital Realty Trust Inc. (NYSE:DLR), Quest Diagnostics Incorporated (NYSE:DGX) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
The following stocks are expected to go Up:
Symbol Company Expected Return Odds By The Following Date JNK SPDR Barclays Capital High Yield Bond ETF 0.48% 100.00% (9 of 9) Friday, March 17th 2017 AGZ iShares Barclays Agency Bond Fund 0.37% 100.00% (8 of 8) Friday, April 28th 2017 AMJ JPMorgan Alerian MLP Index ETN 5.69% 100.00% (7 of 7) Thursday, April 27th 2017 PSDV pSivida Corp. 24.14% 75.00% (6 of 8) Wednesday, April 19th 2017 DLR Digital Realty Trust Inc. 6.97% 91.67% (11 of 12) Friday, April 28th 2017 DGX Quest Diagnostics Incorporated 5.97% 85.00% (17 of 20) Monday, April 10th 2017SPDR Barclays Capital High Yield Bond ETF (NYSE:JNK) - SPDR Lehman High Yield Bond ETF.
iShares Barclays Agency Bond Fund (NYSE:AGZ) - ishares Barclays Agency Bond Fund.
JPMorgan Alerian MLP Index ETN (NYSE:AMJ) - The Bear Stearns Companies, LLC operates as an investment banking, securities and derivatives trading, and clearance and brokerage company. It operates through Capital Markets, Global Clearing Services, and Wealth Management segments. The Capital Markets segment comprises equities, fixed income, and investment banking operations. Fixed income operations include participating in the auction of, and maintaining proprietary positions in, U.S. treasury bills, notes, bonds, and stripped principal and coupon securities; purchase and origination of commercial and residential mortgage loans; dealing in tax-exempt and taxable municipal securities and instruments; offering hedging and arbitrage services; and trading, making markets, and taking proprietary positions in both dollar and non-dollar investment-grade and non-investment-grade corporate debt securities, commercial loans, sovereign and agency securities. The investment banking operations comprise the provision of services in capital raising, strategic advice, mergers and acquisitions, and merchant banking. The Global Clearing Services segment provides trade execution, securities clearing, custody, financing, securities lending, and technology solutions to hedge funds, broker-dealers, registered investment advisors, and high-net-worth individuals. The Wealth Management segment offers private client services including provision of high-net-worth individuals with an institutional level of transactional, wealth management, and advisory services; and asset management services across various asset classes, including money markets, fixed income, currencies, and equities. The company was founded in 1923 and is headquartered in New York, New York. As of May 30, 2008, The Bear Stearns Companies, LLC operates as a subsidiary of JPMorgan Chase & Co..
pSivida Corp. (NASDAQ:PSDV) - pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Medidur, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts..
Digital Realty Trust Inc. (NYSE:DLR) - Digital Realty Trust, Inc., a real estate investment trust (REIT), through its controlling interest in Digital Realty Trust, L.P., engages in the ownership, acquisition, development, redevelopment, and management of technology-related real estate. It focuses on strategically located properties containing applications and operations critical to the day-to-day operations of technology industry tenants and corporate enterprise datacenter users, including the information technology departments of Fortune 1000 companies, and financial services companies. The company s property portfolio consists of Internet gateway properties, corporate datacenter properties, technology manufacturing properties, and regional or national offices of technology companies. As of December 31, 2008, Digital Realty s portfolio consisted of 75 properties, including 62 located in North America and 13 located in Europe. Digital Realty Trust has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its stockholders. The company was founded in 2004 and is headquartered in San Francisco, California with additional offices in Boston, Chicago, Dallas, Los Angeles, New York, Northern Virginia, and Phoenix, as well as in Dublin, London, and Paris..
Quest Diagnostics Incorporated (NYSE:DGX) - Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene-based and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey..
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com